YLYue Li

Yue Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yue Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Jicheng Han

    Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117

    2 shared publications
  • Ningyi Jin

    Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117

    2 shared publications
  • Shanzhi Li

    Academicians Workstation of Jilin Province, Changchun University of Chinese Medicine , Changchun, Jilin 130117

    2 shared publications
  • Xia Yang

    Medical College, Yanbian University , Yanji 133002

    2 shared publications
  • Yaru Li

    Medical College, Yanbian University , Yanji 133002

    2 shared publications
  • Yilong Zhu

    Key Laboratory of Jilin Province for Traditional Chinese Medicine Prevention and Treatment of Infectious Diseases, College of Integrative Medicine, Changchun University of Chinese Medicine, Changchun, China

    2 shared publications

Latest Publications

  • Open Access

    Identification and Functional Characterization of a Novel PRPS1 Variant in X‐Linked Nonsyndromic Hearing Loss: Insights From Zebrafish and Cellular Models

    by Yining Wan, Jinqiu Li, Yingyuan Guo, Fang Guo, Ying Zhao, Yue Li, Xia Yang, Huidan Chen, Shimin Xie, Mingyong Wang, et al.

    Purpose: The study was aimed at identifying the pathogenic gene responsible for X‐linked nonsyndromic hearing loss (NSHL) in a five‐generation Chinese family and at elucidating the gene’s function both in vivo using a zebrafish model and in vitro using PRPS1 knockdown HEI‐OC1 cells.Methods: Exome sequencing (ES) and Sanger sequencing were used to identify the pathogenic variants. A transgenic zebrafish model overexpressing the novel PRPS1 variant (c.494G>A: p.Cys165Tyr) was constructed, and PRPS1 was knocked down in HEI‐OC1 cells using siRNA to explore the underlying mechanisms. Hair cell development and behavior were assessed in zebrafish, and mitochondrial function and cell viability were analyzed in HEI‐OC1 cells.Results: A novel missense variant (c.494G>A: p.Cys165Tyr) in the PRPS1 gene was identified as the pathogenic variant causing progressive X‐linked deafness‐1 (DFNX1). The variant led to hair cell death in zebrafish, with disrupted swimming behavior. In HEI‐OC1 cells, PRPS1 knockdown resulted in downregulation of the nicotinamide adenine dinucleotide (NAD+)/sirtuin 3 (SIRT3)/superoxide dismutase 2 (SOD2) pathway, increased reactive oxygen species (ROS) accumulation, mitochondrial dysfunction, and apoptosis, which were partially rescued by pretreatment with nicotinamide mononucleotide (NMN), a precursor of NAD+.Conclusion: The study reports a novel PRPS1 variant contributing to the variant spectrum of PRPS1 and highlights the role of PRPS1 deficiency in increasing oxidative stress‐induced hair cell apoptosis via the NAD+/SIRT3/SOD2 pathway. These findings provide new insights into the molecular mechanisms of PRPS1‐related hearing loss and potential therapeutic targets.


  • Open Access

    Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice

    by Yue Li, Xia Yang, Jicheng Han, Bing Bai, Yaru Li, Chao Shang, Shanzhi Li, Zhiru Xiu, Zirui Liu, Chenchen Ge, et al.

    Objectives: Inflammatory cytokine secretion and gut microbiota dysbiosis play crucial roles in ulcerative colitis. In this research, the protective effects of peimisine on colitis mice were investigated. Methods: The protective effects were evaluated by the disease activity index, colonic length, hematoxylin–eosin, and AB/PAS Staining. The protective mechanisms were analyzed by ELISA, Western-blot, immunohistochemistry staining, immunofluorescence staining, and 16S rRNA gene analysis. Key findings: The results showed that peimisine treatment could reduce the disease activity index, prevent colonic shortening, and alleviate colon tissue damage. Peimisine treatment also decreased the levels of MCP-1, IL-1β, IL-6, IFN-γ, TNF-α and affected macrophage polarization and Th17/Treg cell balance by downregulating the expression of jak1/2, p-jak1/2, stat1/3, and p-stat1/3. Moreover, peimisine treatment significantly increased the abundances of beneficial microbes (e.g. Ruminococcaceae UCG-014 and Lachnospiraceae_NK4A136_group) and decreased the abundances of harmful microbes (e.g. Bacteroides and Escherichia). Conclusions: Peimisine can ameliorate colitis by inhibiting Jak–Stat signaling pathway, reversing gut microbiota alterations, suppressing macrophage M1 polarization, maintaining the Th17/Treg cell balance, and reducing sustained inflammatory cytokines-related inflammatory injury.


  • Open Access

    Betulinic acid inhibits growth of hepatoma cells through activating the NCOA4-mediated ferritinophagy pathway

    by Zhiru Xiu, Yilong Zhu, Shanzhi Li, Yaru Li, Xia Yang, Yue Li, Gaojie Song, Ningyi Jin, Jinbo Fang, Jicheng Han, et al.